An observational study in Coronary Artery Disease, sponsored by Fundación EPIC. Active, not recruiting at 19 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Fundación EPIC · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Coronary Artery Disease by Fundación EPIC — 13 open to participants now, 20 under way, none of them phase 3. Coronary Artery Disease · Fundación EPIC.
Among the 33 studies in Coronary Artery Disease by Fundación EPIC, this one is the 6th largest by enrollment of the 20 observational ones that give a count, is one of 6 that started in 2024, is one of 20 observational ones, reaches primary completion later than 5 of the 19 other live ones, and was the 23rd registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →13 of the 33 studies in Coronary Artery Disease by Fundación EPIC are open now, in 7 countries. Recruiting first, the newest first:
Fundación EPIC · Sites in Spain
Ages 18+
Fundación EPIC · Sites in United States, Belgium, Spain and 1 more country
Ages 18–85
Fundación EPIC · Sites in Spain
Ages 18+
Fundación EPIC · Sites in Spain
Ages 18+
Fundación EPIC · Sites in Hong Kong
Ages 18+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 501 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 200 across the 13 interventional studies, 375 across the 20 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fundación EPIC is the lead sponsor of 48 studies on the registry; 19 are open to participants now.
10 of the studies in Coronary Artery Disease by Fundación EPIC that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06448637Fundación EPICDRUG RELEASING BALL vs. PHARMACOACTIVE STENT IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY) IN LARGE VESSELS: MORPHOLOGICAL ANALYSIS AND FUNCTION VASOMOTOR (DEBORA STUDY) | 2026-12-01 |
| NCT05788432Fundación EPICSequent Extended Study | 2026-12-01 |
| NCT05617599Fundación EPICSUPRAFLEX CRUZ PMCF Study ( rEpic05 ) | 2026-12-01 |
| NCT06321757Fundación EPICPREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients | 2026-12-30 |
| NCT07260474Fundación EPICComparison of the Amplatzer Amulet Versus LAmbre Device for Left Atrial Appendage Closure | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 33 studies in Coronary Artery Disease by Fundación EPIC, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Post-market, prospective, observational, multicenter, non-intervention study, to demonstrate the effectiveness of drug-coated ballon (DCB)therapy in real-world patients with small native vessel coronary artery disease, and to demonstrate the safety of short dual antiplatelet therapy (7 days) in high-bleeding risk patients with native small vessel coronary artery disease treated with DCB therapy. A percutaneous coronary intervention (PCI) with DCB will be performed in patients with native vessel coronary artery disease based on the criterion of the treating physician.
Post-market, prospective, multicenter, non-intervention study, to demonstrate the effectiveness of drug-coated ballon therapy in real-world patients with small native vessel coronary artery disease, and to demonstrate the safety of short dual antiplatelet therapy (7 days) in high-bleeding risk patients with native small vessel coronary artery disease treated with DCB therapy. A PCI with DCB will be performed in patients with native vessel coronary artery disease based on the criterion of the treating physician. The angiographic study will be analyzed in a core lab (icicorelab) blinded to the procedural outcomes and the patients' follow-up.
As per clinical practice, 1-year clinical follow-up of all the patients will be conducted with a first assessment at 30 days, a second assessment at 6 months, and one final assessment at 12 months.
Should the patient have an elevated bleeding risk -defined as concomitant therapy with oral anticoagulation or a PRECISE-DAPT score ≥ 25- patients will be included in a high-bleeding risk substudy. The antiplatelet therapy regime will be administered according to the local investigator and the treating medical team.
drug-coated ballon therapy in real-world patients with small native vessel coronary artery disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with:
syndrome or silent angina with an indication for PCI.
Exclusion Criteria:
Patients with:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
\- Patients with small native vessel coronary artery disease y/or patients with High Bleeding Risk
Device: Percutaneous Coronary Intervention with DCB and DAPT
* Patients with PCI (DCB) + standard DAPT standard dual antiplatelet therapy (DAPT) * Patients with PCI (DCB) + short DAPT
Effectiveness of DCB therapy
Incidence of MACE, which is a composite endpoint including cardiac mortality, myocardial infarction, and new revascularization of the target lesion
Time frame: 1 year
Cardiac death
Incidence of Cardiac death
Time frame: 1 year
All-cause mortality
Incidence of All-cause mortality
Time frame: 1 year
Target vessel myocardial infarction
Incidence of Target vessel myocardial infarction
Time frame: 1 year
New target lesion revascularization (TLR)
Incidence of New target lesion revascularization (TLR)
Time frame: 1 year
Target vessel failure (TVF)
Incidence of Target vessel failure (TVF)
Time frame: 1 year
Major bleeding
Bleeding defined as BARC (Bleeding Academic Research Consortium) criteria 2,3 or 5
Time frame: 1 year
Minor bleeding
Anemia, defined as Hb\<12g/dL for women and \<13g/dL for men
Time frame: 1 year
1-year MACE indicende (cardiac mortality, myocardial infarction, and new revascularization of the target lesion) in high-bleeding risk patients treated with a short dual antiplatelet treatment (7 days)
safety analysis of short DAP (dual antiplatelet therapy) in terms of thrombotic risk after PCI
Time frame: 1 year
Started Feb 2024 (actual). Primary completion is estimated for Dec 2026, 34 months after the start.
Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 34 months is below that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación EPIC